Abstract

The quality of chimeric antigen receptor (CAR)-T cell products, namely, memory and exhaustion markers, affects the long-term functionality of CAR-T cells. We previously reported that piggyBac (PB) transposon-mediated CD19 CAR-T cells exhibit a memory-rich phenotype that is characterized by the high proportion of CD45RA+/C-C chemokine receptor type 7 (CCR7)+ T-cell fraction. To further investigate the favorable phenotype of PB-CD19 CAR-T cells, we generated PB-CD19 CAR-T cells from CD45RA+ and CD45RA− peripheral blood mononuclear cells (PBMCs) (RA+ CAR and RA− CAR, respectively), and compared their phenotypes and antitumor activity. RA+ CAR-T cells showed better transient gene transfer efficiency 24 h after transduction and superior expansion capacity after 14 days of culture than those shown by RA− CAR-T cells. RA+ CAR-T cells exhibited dominant CD8 expression, decreased expression of the exhaustion marker programmed cell death protein-1 (PD-1) and T-cell senescence marker CD57, and enriched naïve/stem cell memory fraction, which are associated with the longevity of CAR-T cells. Transcriptome analysis showed that canonical exhaustion markers were downregulated in RA+ CAR-T, even after antigen stimulation. Although antigen stimulation could increase CAR expression, leading to tonic CAR signaling and exhaustion, the expression of CAR molecules on cell surface after antigen stimulation in RA+ CAR-T cells was controlled at a relatively lower level than that in RA− CAR-T cells. In the in vivo stress test, RA+ CAR-T cells achieved prolonged tumor control with expansion of CAR-T cells compared with RA− CAR-T cells. CAR-T cells were not detected in the control or RA− CAR-T cells but RA+ CAR-T cells were expanded even after 50 days of treatment, as confirmed by sequential bone marrow aspiration. Our results suggest that PB-mediated RA+ CAR-T cells exhibit a memory-rich phenotype and superior antitumor function, thus CD45RA+ PBMCs might be considered an efficient starting material for PB-CAR-T cell manufacturing. This novel approach will be beneficial for effective treatment of B cell malignancies.

Highlights

  • Chimeric antigen receptor (CAR)-T cell therapies targeting CD19 have achieved spectacular success for B-cell malignancies, long-term remission occurs only in half of the patients with B-cell malignancies [1,2,3,4,5,6]

  • We found that CD45RA+ peripheral blood mononuclear cells (PBMCs) were susceptible to the introduction of chimeric antigen receptor (CAR) transgene by electroporation, and RA+ CAR-T cells exhibited superior expansion capacity than RA− CAR-T Cells

  • CD45RA-positive PBMC selection from PBMCs starting from PB-CAR-T cell manufacturing would be important to improve the efficacy of the therapy

Read more

Summary

Introduction

Chimeric antigen receptor (CAR)-T cell therapies targeting CD19 have achieved spectacular success for B-cell malignancies, long-term remission occurs only in half of the patients with B-cell malignancies [1,2,3,4,5,6]. Enhancing the long-term functionality of CAR-T cells without affecting their anti-tumor potency is important. Pre-activation of T cells by anti-CD3 and CD28 antibodies—an indispensable step for retroviral or lentiviral gene transfer into T cells—strongly induces T-cell differentiation and exhaustion; various efforts to obtain memory-rich CAR-T cells have been attempted, namely, the use of interleukin (IL)-7 and IL-15 cocktails instead of IL-2 or transient stimulation with anti-CD3 and CD28 antibodies [7, 10]

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.